Recombinant insulin glargine combined treatment of type 2 diabetes nateglinide clinical observation.docVIP

 PAGE \* MERGEFORMAT 7 Recombinant insulin glargine combined treatment of type 2 diabetes nateglinide clinical observation [Abstract] Objective To observe the restructuring of insulin glargine (a long show-lin) combined nateglinide treatment of secondary failure of sulfonylurea drug efficacy in patients with type 2 diabetes. Methods 32 patients with secondary sulfonylurea failure in diabetic patients given recombinant insulin glargine at bedtime subcutaneous injection of 1 8 hours, adjusting the dose (12 ~ 26 u) the fasting blood glucose control in the 5.0 ~ 6.5 mmol / L. At the same time the United nateglinide, dosage adjustment is to make the meal blood glucose control in the 6.0 ~ 8.0 mmol / L, nateglinide meal 30 ~ 60 mg, for 3 months was observed in patients with fasting plasma glucose and postprandial 2 h blood glucose, HbA1c, and BMI. Results after 3 months treatment fasting blood glucose compared with patients before treatment [(5.1 + -1.3) mmol / Lvs (12.3 + -4.2) mmol / L]. postprandial 2 h blood glucose [(8.2 + -3.8) mmol / L vs (17.5 + -6.1) mmol / L], HbA1c [(7.3 + -1.1)% vs (11.6 + -1.3)%], were significantly decreased (P lt;0.01). BMI [(25.8 + -4.1) kg/m2vs (25.6 + -3.5) kg/m2], no statistical significance. concluded that the recombinant insulin glargine combined nateglinide in controlling secondary sulfonylurea failure in patients with type 2 diabetes blood sugar has a good effect. [Keywords:] recombinant insulin glargine; nateglinide; diabetes Sulfonylureas is an application longest widest range of oral hypoglycemic drugs. These drugs by stimulating -cell secretion of insulin and glucose play a role in the diagnosis of Type 2 diabetes beginning of the islet cell function has decreased by 50% or more, with the course of prolonged -cell function gradually declined. so secondary sulfonylurea failure in patients with type 2 diabetes is very common in clinical practice, this research combined with recombinant insulin glargine treatment Nat